{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T19:27:21Z","timestamp":1772220441971,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Science Center","award":["2013\/09\/\/N\/NZ7\/\/02143"],"award-info":[{"award-number":["2013\/09\/\/N\/NZ7\/\/02143"]}]},{"name":"Institute of Pharmacology, Polish Academy of Sciences, Krak\u00f3w, Poland"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.pharep.2018.04.009","type":"journal-article","created":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T11:20:36Z","timestamp":1525173636000},"page":"1023-1031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex"],"prefix":"10.1007","volume":"70","author":[{"given":"Katarzyna","family":"Kami\u0144ska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"G\u00f3rska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Noworyta-Soko\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Wojtas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zofia","family":"Rog\u00f3\u017c","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystyna","family":"Go\u0142embiowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"6","key":"10.1016\/j.pharep.2018.04.009_bib0005","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4088\/JCP.v68n0602","article-title":"Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis","volume":"68","author":"Papakostas","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharep.2018.04.009_bib0010","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/phar.1204","article-title":"Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature","volume":"33","author":"Wright","year":"2013","journal-title":"Pharmacotheraphy"},{"issue":"1","key":"10.1016\/j.pharep.2018.04.009_bib0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40263-012-0029-7","article-title":"Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression","volume":"27","author":"Kato","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharep.2018.04.009_bib0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacol (Berl)"},{"issue":"1","key":"10.1016\/j.pharep.2018.04.009_bib0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.pharep.2018.04.009_bib0030","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-0173(99)00046-6","article-title":"Serotonin Model of schizophrenia: emerging role of glutamate mechanisms","volume":"31","author":"Aghajanian","year":"2000","journal-title":"Brai Res Rev"},{"key":"10.1016\/j.pharep.2018.04.009_bib0035","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/0028-3908(95)00101-B","article-title":"The interactions of typical and atypical antipsychotics with the (\u2212)2,5-dimethoxy-4-methamphetamine (DOM) discriminative stimulus","volume":"34","author":"Fiorella","year":"1995","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pharep.2018.04.009_bib0040","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1017\/S1461145707008176","article-title":"Divergent effects of increased serotonergic activity on psychophysiological parameters of human attention","volume":"11","author":"Oranje","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.pharep.2018.04.009_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-011-2463-5","article-title":"Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter\u2013a review of current understanding of its mechanism of action","volume":"219","author":"Zhong","year":"2012","journal-title":"Psychopharmacol (Berl)"},{"issue":"227","key":"10.1016\/j.pharep.2018.04.009_bib0050","first-page":"506","article-title":"Antidepressant polypharmacy and the potential of pharmacokinetic interactions: doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism","volume":"13","author":"Paulzen","year":"2017","journal-title":"J Affect Disord"},{"issue":"5","key":"10.1016\/j.pharep.2018.04.009_bib0055","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00023210-200923050-00006","article-title":"Mirtazapine: a review of its use in major depression and other psychiatric disorders","volume":"23","author":"Croom","year":"2009","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.pharep.2018.04.009_bib0060","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S1734-1140(13)71472-5","article-title":"Effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex","volume":"65","author":"Kami\u0144ska","year":"2013","journal-title":"Pharmacol Rep"},{"issue":"6","key":"10.1016\/j.pharep.2018.04.009_bib0065","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.pharep.2014.06.009","article-title":"The effect of risperidone on the mirtazapine-induced changes in extracellular monoamines in the rat frontal cortex","volume":"66","author":"Kami\u0144ska","year":"2014","journal-title":"Pharmacol Rep"},{"issue":"1","key":"10.1016\/j.pharep.2018.04.009_bib0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pharep.2016.09.010","article-title":"Risperidone and escitalopram co-administration: a potential treatment of schizophrenia symptoms with less side effects","volume":"69","author":"Kami\u0144ska","year":"2017","journal-title":"Pharmacol Rep"},{"issue":"3","key":"10.1016\/j.pharep.2018.04.009_bib0075","first-page":"471","article-title":"The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats","volume":"67","author":"Kami\u0144ska","year":"2016","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharep.2018.04.009_bib0080","first-page":"985","volume":"24","author":"Simon","year":"1969","journal-title":"Therapie"},{"key":"10.1016\/j.pharep.2018.04.009_bib0085","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.pbb.2008.04.011","article-title":"Prefrontal cortex-nucleus accumbens interaction: in vivo modulation by dopamine and glutamate in the prefrontal cortex","volume":"90","author":"Del Arco","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/j.pharep.2018.04.009_bib0090","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(98)00308-2","article-title":"Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens","volume":"351","author":"Ichikawa","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharep.2018.04.009_bib0095","first-page":"819","article-title":"Mechanism of action of atypical antipsychotic drugs","volume":"58","author":"Meltzer","year":"2002","journal-title":"Neuropharmacol Fifth Gener Progress Am Coll Neuropharmacol"},{"issue":"1\u20133","key":"10.1016\/j.pharep.2018.04.009_bib0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0014-2999(96)00150-1","article-title":"Ipsapirone enhances the dopamine outflow via 5-moemoeceptors in the rat prefrontal cortex","volume":"30","author":"W\u0119dzony","year":"1996","journal-title":"Eur J Pharmacol"},{"issue":"25","key":"10.1016\/j.pharep.2018.04.009_bib0105","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.2174\/092986706778521805","article-title":"Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies?","volume":"13","author":"Di Giovanni","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.pharep.2018.04.009_bib0110","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin2a receptors in pyramidal and gabaergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cereb Cortex"},{"issue":"1\u20132","key":"10.1016\/j.pharep.2018.04.009_bib0115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02244785","article-title":"Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?","volume":"115","author":"Tanda","year":"1994","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.pharep.2018.04.009_bib0120","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjp.0703139","article-title":"Matsuda T. Postsynaptic 5-Hydroxytryptamine1A receptor activation increases in vivo dopamine release in rat prefrontal cortex","volume":"129","author":"Sakaue","year":"2000","journal-title":"Brit J Pharmacol"},{"key":"10.1016\/j.pharep.2018.04.009_bib0125","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0022-3565(25)20732-7","article-title":"Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes","volume":"251","author":"Kalivas","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2018.04.009_bib0130","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/syn.20853","article-title":"Effects of S-citalopram, citalopram and R-citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, NMDA receptor-mediated transmission in the medial prefrontal cortex and cognitive function in the rat","volume":"65","author":"Schilstr\u00f6m","year":"2011","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.pharep.2018.04.009_bib0135","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13195-017-0298-y","article-title":"Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-\u03b2 levels in early-stage Alzheimer\u2019s-like disease in mice","volume":"9","author":"von Linstow","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.1016\/j.pharep.2018.04.009_bib0140","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0028-3908(01)00087-9","article-title":"Noradrenergic modulation of serotonin release in rat dorsal and median raph\u00e9 nuclei via alpha(1) and alpha(2A) adrenoceptors","volume":"41","author":"Hopwood","year":"2001","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pharep.2018.04.009_bib0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000104877","article-title":"Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the in the mouse forced swim test","volume":"80","author":"Dhir","year":"2007","journal-title":"Pharmacology"},{"issue":"3\u20134","key":"10.1016\/j.pharep.2018.04.009_bib0150","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0014-2999(84)90618-6","article-title":"Idazoxan (RX 781094) selectively antagonizes alpha 2-adrenoceptors on rat central neurons","volume":"105","author":"Freedman","year":"1984","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2018.04.009_bib0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0028-3908(80)90187-2","article-title":"Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoreceptor antagonists","volume":"19","author":"Baraban","year":"1980","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharep.2018.04.009_bib0160","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bbr.2006.04.004","article-title":"Behavioural effects of chronic haloperidol and risperidone treatment in rats","volume":"171","author":"Karl","year":"2006","journal-title":"Behav Brain Res"},{"issue":"6","key":"10.1016\/j.pharep.2018.04.009_bib0165","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1176\/ajp.154.6.799","article-title":"Does risperidone improve verbal working memory in treatment-resistant schizophrenia?","volume":"154","author":"Green","year":"1997","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.pharep.2018.04.009_bib0170","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00213-003-1449-3","article-title":"Comparison of the effects of antipsychotics on a delayed radial maze task in the rat","volume":"168","author":"Wolff","year":"2003","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.pharep.2018.04.009_bib0175","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2165\/00023210-199606020-00005","article-title":"Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia","volume":"6","author":"Evins","year":"1996","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.pharep.2018.04.009_bib0180","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.pharep.2015.04.006","article-title":"The effect of combined treatment with risperidone and antidepressants on the MK-801-induced deficits in the social interaction test in rats","volume":"67","author":"Kami\u0144ska","year":"2015","journal-title":"Pharmacol Rep"},{"issue":"5","key":"10.1016\/j.pharep.2018.04.009_bib0185","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S1734-1140(13)71499-3","article-title":"Effect of combined treatment with mirtazapine and risperidone on the MK-801-induced changes in the object recognition test in mice","volume":"65","author":"Rogoz","year":"2013","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2018.04.009_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.04.013","article-title":"Short- and long-term effects of risperidone on catalepsy sensitisation and acquisition of conditioned avoidance response: adolescent vs adult rats","volume":"121","author":"Moe","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharep.2018.04.009_bib0195","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2008.08.002","article-title":"Evaluation of age and sex differences in locomotion and catalepsy during repeated administration of haloperidol and clozapine in adolescent and adult rats","volume":"58","author":"Wiley","year":"2008","journal-title":"Pharmacol Res"},{"issue":"13","key":"10.1016\/j.pharep.2018.04.009_bib0200","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/npp.2012.139","article-title":"Clozapine-induced locomotor suppression is mediated by 5-HT2A receptors in the forebrain","volume":"37","author":"McOmish","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pharep.2018.04.009_bib0205","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0306-4522(94)90178-3","article-title":"Mechanisms of antihistamine-induced sedation in the human brain: H1 receptor activation reduces a background leakage potassium current","volume":"59","author":"Reiner","year":"1994","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.pharep.2018.04.009_bib0210","first-page":"441","article-title":"Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects","volume":"50","author":"Kreutner","year":"2000","journal-title":"Arzneimittelforschung"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114017308113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114017308113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:37:40Z","timestamp":1752611860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2018.04.009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1734114017308113"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2018.04.009","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2018.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}